Pete de Spain
Investor Relations Contact chez KURA ONCOLOGY, INC.
Profil
Pete de Spain currently works at Kura Oncology, Inc., as EVP-Investor Relations & Corporate Communications from 2023.
Mr. de Spain also formerly worked at Prometheus Laboratories, Inc., as Director-Investor Relations & Communications from 2008 to 2010, Favrille, Inc., as Head-Investor Relations & Corporate Communications, MEI Pharma, Inc., as Vice President-Investor Relations & Communications from 2014 to 2017, National Investor Relations Institute, as President-San Diego Chapter, NIRI San Diego, as Co-President, Anadys Pharmaceuticals, Inc., as Head-Investor Relations & Corporate Communications from 2004 to 2005, Sunrise Medical, Inc., as Head-Investor Relations & Corporate Communications from 1993 to 1999, and Sequenom, Inc., as Head-Investor Relations & Corporate Communications from 1999 to 2004.
Mr. de Spain received his undergraduate degree from San Diego State University.
Postes actifs de Pete de Spain
| Sociétés | Poste | Début |
|---|---|---|
| KURA ONCOLOGY, INC. | Investor Relations Contact | 01/10/2017 |
Anciens postes connus de Pete de Spain
| Sociétés | Poste | Fin |
|---|---|---|
| MEI PHARMA, INC. | Investor Relations Contact | 01/01/2017 |
Prometheus Laboratories, Inc.
 Prometheus Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Prometheus Laboratories, Inc. develops and commercializes novel pharmaceutical and diagnostic products. Its enables physicians to provide individualized patient care. It applies the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and applies it to oncology. The firms markets and promotes pharmaceutical products and complementary proprietary diagnostic testing services. The company was founded by Jonathan Braun, Stephan R. Targan, Michael J. Walsh, and Scott L. Glenn in 1995 and is headquartered in San Diego, CA. | Public Communications Contact | 01/01/2010 |
| Favrille, Inc. | Public Communications Contact | 22/04/2009 |
Anadys Pharmaceuticals, Inc.
 Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Investor Relations Contact | 01/01/2005 |
| SEQUENOM, INC. | Public Communications Contact | 01/01/2004 |
Formation de Pete de Spain
| San Diego State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| KURA ONCOLOGY, INC. | Health Technology |
| MEI PHARMA, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Sequenom, Inc.
 Sequenom, Inc. Medical SpecialtiesHealth Technology Sequenom, Inc. engages in the provision of early patient management information. It develops and commercializes molecular diagnostic testing services that serve women's health and oncology markets. The company was founded by Hubert Koester and Charles R. Cantor in October 09, 1996 and is headquartered in Burlington, NC. | Health Technology |
| Favrille, Inc. | Health Technology |
Anadys Pharmaceuticals, Inc.
Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Health Technology |
Prometheus Laboratories, Inc.
Prometheus Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Prometheus Laboratories, Inc. develops and commercializes novel pharmaceutical and diagnostic products. Its enables physicians to provide individualized patient care. It applies the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and applies it to oncology. The firms markets and promotes pharmaceutical products and complementary proprietary diagnostic testing services. The company was founded by Jonathan Braun, Stephan R. Targan, Michael J. Walsh, and Scott L. Glenn in 1995 and is headquartered in San Diego, CA. | Health Technology |
National Investor Relations Institute
 National Investor Relations Institute Miscellaneous Commercial ServicesCommercial Services National Investor Relations Institute operates as an association of corporate officers and investor relations consultants responsible for communication among corporate management, shareholders, securities analysts and other financial community constituents. The company was founded by DeWitt C. Morrill in 1969 and is headquartered in Alexandria, VA. | Commercial Services |
| NIRI San Diego | |
| Sunrise Medical, Inc. | Health Technology |
